wire
"Science Wire" gives access to latest science news from research centers and R&D companies.- Add this page to your bookmarks
- news.myScience.ch: "News from the Lab". A selection of science news.
Category
- Administration/Government
- Agronomy/Food Science
- Architecture
- Arts and Design
- Astronomy
- Business/Economics
- Careers/Employment
- Chemistry
- Civil Engineering/Traffic Engineering
- Computer Science/Telecom
- Earth Sciences
- Education/Continuing Education
- Environmental Sciences
- Event
- History/Archeology
- Law/Forensics
- Life Sciences
- Literature/Linguistics
- Mathematics
- Mechanical Engineering/Mechanics
- Media Sciences/Political Sciences
- Medicine/Pharmacology
- Microtechnics/Electroengineering
- Pedagogy/Education Science
- Philosophy
- Physics/Material Science
- Psychology
- Social Sciences
- Sport Sciences
- Study of Religions
- Veterinary Science
Company/Institution
ABB | AGROSCOPE | CERN | EMPA | ETHZ | FHNW | FMI | HSLU | KALAIDOS | NOVARTIS | PSI | ROCHE | SBF | SBFI | SNF | UNIBAS | UNIBE | UNIFR | UNIGE | UNIL | UNINE | UZH | VOGELWARTE | ZHAW |
Novartis
Medicine/Pharmacology - Life Sciences
17.05.2013
Novartis drug Afinitor significantly extended time without disease progression in women with HER2 positive advanced breast cancer
Everolimus plus trastuzumab and vinorelbine met primary endpoint of extending PFS compared to placebo plus trastuzumab and vinorelbine after prior therapy Results of Phase III trial, BOLERO-3,
Everolimus plus trastuzumab and vinorelbine met primary endpoint of extending PFS compared to placebo plus trastuzumab and vinorelbine after prior therapy Results of Phase III trial, BOLERO-3,
Medicine/Pharmacology - Social Sciences
17.05.2013
Novartis wins GBCHealth Business Action on Health Award for social ventures initiative
Medicine/Pharmacology
10.05.2013
Novartis drug Ilaris approved by FDA to treat active systemic juvenile idiopathic arthritis, a serious form of childhood arthritis
Ilaris (canakinumab) is the first interleukin-1 beta inhibitor for the treatment of SJIA and the only treatment approved specifically for SJIA that is given as a monthly subcutaneous injection
Ilaris (canakinumab) is the first interleukin-1 beta inhibitor for the treatment of SJIA and the only treatment approved specifically for SJIA that is given as a monthly subcutaneous injection
Medicine/Pharmacology - Event
08.05.2013
Real-world data at ARVO highlight transformational outcomes seen with Lucentis , including lower injection frequency than in original clinical trials
UK real world study shows 59% reduction of legal blindness attributable to wet AMD since introduction of Lucentis with 9.7 injections spread over 5 years New one year REPAIR data shows visual acuity improvement of 14 letters with an average of 3.6 Lucentis injections in myopic CNV patients Largest Lucentis meta-analysis, over 10,000 patients, confirms well-established safety profile reported from extensive clinical trials and
UK real world study shows 59% reduction of legal blindness attributable to wet AMD since introduction of Lucentis with 9.7 injections spread over 5 years New one year REPAIR data shows visual acuity improvement of 14 letters with an average of 3.6 Lucentis injections in myopic CNV patients Largest Lucentis meta-analysis, over 10,000 patients, confirms well-established safety profile reported from extensive clinical trials and
Medicine/Pharmacology - Business/Economics
25.04.2013
Novartis signs on to support Malaria No More’s Power of One campaign to stride towards a future without malaria
Power of One donation campaign harnesses the latest web and mobile technology to rally the global public to fight malaria Novartis will donate up to three million courses of pediatric antimalar
Power of One donation campaign harnesses the latest web and mobile technology to rally the global public to fight malaria Novartis will donate up to three million courses of pediatric antimalar
Business/Economics - Medicine/Pharmacology
24.04.2013
Novartis delivered solid performance in the first quarter, with eight key regulatory approvals and all divisions contributing to growth
Sustained commitment to innovation resulted in eight key approvals in the EU and US and strong pipeline progress EMA approved Jetrea, Bexsero , a new indication for Ilaris and a line extensio
Sustained commitment to innovation resulted in eight key approvals in the EU and US and strong pipeline progress EMA approved Jetrea, Bexsero , a new indication for Ilaris and a line extensio
Medicine/Pharmacology
24.04.2013
Novartis discloses compensation for new Chairman and Chairman ad-interim
Dr. Joerg Reinhardt to receive total annual compensation of CHF 3.8 million through combination of cash and stock for serving as Chairman of Novartis.
Dr. Joerg Reinhardt to receive total annual compensation of CHF 3.8 million through combination of cash and stock for serving as Chairman of Novartis.
Medicine/Pharmacology
23.04.2013
Novartis once-daily QVA149 shows superior efficacy in reducing exacerbations, improving lung function and quality of life in COPD patients
SPARK results published in Lancet Respiratory Medicine showed that dual bronchodilator QVA149 significantly reduced the rate of moderate or severe COPD exacerbations compared to glycopyrronium 50 mcg QVA149 significantly reduced the rate of all COPD exacerbations compared to open-label tiotropium 18 mcg and glycopyrronium Basel, April 23, 2013 - Results from the 64-week SPARK study published today in Lancet Respiratory Medicine showe
SPARK results published in Lancet Respiratory Medicine showed that dual bronchodilator QVA149 significantly reduced the rate of moderate or severe COPD exacerbations compared to glycopyrronium 50 mcg QVA149 significantly reduced the rate of all COPD exacerbations compared to open-label tiotropium 18 mcg and glycopyrronium Basel, April 23, 2013 - Results from the 64-week SPARK study published today in Lancet Respiratory Medicine showe
Medicine/Pharmacology
19.04.2013
Alcon announces FDA approval of Simbrinza(TM) Suspension, a new beta blocker-free, fixed-combination therapy for glaucoma patients
Simbrinza offers a wide range of treatment possibilities due to its strong efficacy, providing sustained control and a 21%-35% reduction in intraocular pressure , , Combines Brinzolamide 1.
Simbrinza offers a wide range of treatment possibilities due to its strong efficacy, providing sustained control and a 21%-35% reduction in intraocular pressure , , Combines Brinzolamide 1.
Medicine/Pharmacology
01.04.2013
Supreme Court denial of Glivec patent clarifies limited intellectual property protection
Patent denied despite global recognition of Glivec as a life-saving, breakthrough drug for certain forms of cancer, with patents granted in nearly 40 countries Novartis has never been grant
Patent denied despite global recognition of Glivec as a life-saving, breakthrough drug for certain forms of cancer, with patents granted in nearly 40 countries Novartis has never been grant
Medicine/Pharmacology - Life Sciences
26.03.2013
Novartis confirms growing Gilenya clinical and real-world experience as number of patients treated increases to over 63,000
Growing global evidence base reinforces consistent and sustained efficacy of first once-daily oral multiple sclerosis treatment Gilenya is the only approved MS treatment shown to consistently decrease brain volume loss across studies with a significant effect seen as early as six months Low rate of brain volume loss with Gilenya sustained for up to four years in Phase III studies and for up to seven years in patients after complet
Growing global evidence base reinforces consistent and sustained efficacy of first once-daily oral multiple sclerosis treatment Gilenya is the only approved MS treatment shown to consistently decrease brain volume loss across studies with a significant effect seen as early as six months Low rate of brain volume loss with Gilenya sustained for up to four years in Phase III studies and for up to seven years in patients after complet
Medicine/Pharmacology
21.03.2013
New analysis shows Novartis drug Gilenya significantly reduced rate of brain volume loss across three large Phase III studies
Data show reductions in rate of brain volume loss by about one-third compared to interferon beta-1a IM or placebo in studies with over 3,600 patients with relapsing MS Gilenya is the first oral disease modifying treatment to show consistent effect on brain volume loss, an important indicator of disease progression Analysis of FREEDOMS II, a Phase III study, confirms Gilenya consistently reduces annualized relapse rates across disease
Data show reductions in rate of brain volume loss by about one-third compared to interferon beta-1a IM or placebo in studies with over 3,600 patients with relapsing MS Gilenya is the first oral disease modifying treatment to show consistent effect on brain volume loss, an important indicator of disease progression Analysis of FREEDOMS II, a Phase III study, confirms Gilenya consistently reduces annualized relapse rates across disease
Medicine/Pharmacology
18.03.2013
Alcon announces EU approval of Jetrea , first and only eye drug to treat sight-threatening vitreomacular traction and macular hole
Jetrea represents a breakthrough for patients with vitreomacular traction (VMT), a sight-threatening progressive condition, if left untreated One-time intravitreal injection
Jetrea represents a breakthrough for patients with vitreomacular traction (VMT), a sight-threatening progressive condition, if left untreated One-time intravitreal injection
Medicine/Pharmacology
15.03.2013
Novartis compound LDK378 receives FDA Breakthrough Therapy designation for ALK+ non-small cell lung cancer
LDK378 is an investigational selective inhibitor of ALK , a target found in a variety of cancers including metastatic non-small cell lung cancer (NSCLC) Breakthrough Therapy designation is based on positive early data in patients with ALK+ NSCLC who have been previously treated with crizotinib First filing for LDK378 anticipated in early 2014 Basel, March 15, 2013 - Novartis announced today that its investigational compoun
LDK378 is an investigational selective inhibitor of ALK , a target found in a variety of cancers including metastatic non-small cell lung cancer (NSCLC) Breakthrough Therapy designation is based on positive early data in patients with ALK+ NSCLC who have been previously treated with crizotinib First filing for LDK378 anticipated in early 2014 Basel, March 15, 2013 - Novartis announced today that its investigational compoun
Medicine/Pharmacology
13.03.2013
Novartis data at AAN reinforces commitment to address high unmet medical need and to provide a treatment at every stage of multiple sclerosis
New data from three Phase III studies underlines efficacy and adds to growing global experience with Gilenya in more than 50,000 patients worldwide Data from over 500 patients treated for up to four years reinforces the known, manageable safety profile of once-daily oral Gilenya Progress reported with Novartis portfolio in studies of patients with primary-progressive MS and secondary-progressive MS, form
New data from three Phase III studies underlines efficacy and adds to growing global experience with Gilenya in more than 50,000 patients worldwide Data from over 500 patients treated for up to four years reinforces the known, manageable safety profile of once-daily oral Gilenya Progress reported with Novartis portfolio in studies of patients with primary-progressive MS and secondary-progressive MS, form
Medicine/Pharmacology
01.03.2013
Novartis receives EU approval for Ilaris in patients suffering acute gouty arthritis attacks who cannot gain relief from current treatments
Ilaris is the first biologic approved in the EU for symptomatic pain relief in a gouty arthritis indication, and is administered in a single, subcutaneous injection The intense infl
Ilaris is the first biologic approved in the EU for symptomatic pain relief in a gouty arthritis indication, and is administered in a single, subcutaneous injection The intense infl
Medicine/Pharmacology
28.02.2013
Novartis collaboration aims to eliminate rheumatic heart disease (RHD) in Zambia, Africa
RHD has been eliminated in most developed nations, but sub-Saharan Africa studies show at least 2-3% of school-age children suffer from this often fatal disease Collaboration between Novarti
RHD has been eliminated in most developed nations, but sub-Saharan Africa studies show at least 2-3% of school-age children suffer from this often fatal disease Collaboration between Novarti
Medicine/Pharmacology - Life Sciences
24.02.2013
Novartis reports Phase III data showing omalizumab improved itch in patients with a chronic form of hives who failed standard therapy[1]
Study published in NEJM today and presented tomorrow met primary endpoint in moderate to severe refractory chronic idiopathic/spontaneous urticaria (CIU/CSU) Up to two-thirds (66%) of omalizu
Study published in NEJM today and presented tomorrow met primary endpoint in moderate to severe refractory chronic idiopathic/spontaneous urticaria (CIU/CSU) Up to two-thirds (66%) of omalizu
Medicine/Pharmacology - Business/Economics
22.02.2013
Shareholders approve all resolutions proposed by Novartis Board of Directors - Dr. Joerg Reinhardt to succeed as Chairman following transition period
Shareholders approve 16 th consecutive dividend increase to CHF 2.30 (+2%) per share for 2012, representing a payout of approximately 65% of net income from continuing operations New com
Shareholders approve 16 th consecutive dividend increase to CHF 2.30 (+2%) per share for 2012, representing a payout of approximately 65% of net income from continuing operations New com
Medicine/Pharmacology - Business/Economics
19.02.2013
Novartis Board of Directors and Dr. Daniel Vasella agree to cancel the non-compete agreement and all related compensation; Decision taken to address concerns of stakeholders
Basel, 19 February 2013 - Novartis announced that the Novartis Board of Directors and Daniel Vasella have agreed to cancel his non-compete agreement with Novartis and all related conditional compensation.
Basel, 19 February 2013 - Novartis announced that the Novartis Board of Directors and Daniel Vasella have agreed to cancel his non-compete agreement with Novartis and all related conditional compensation.
Medicine/Pharmacology - Administration/Government
15.02.2013
Novartis drug Zortress is first in over a decade approved by FDA to prevent organ rejection in adult liver transplant patients
Zortress is the first mTOR inhibitor approved to prevent organ rejection in adult liver transplant patients in the US, where it is already approved for kidney transplantation Approval based on
Zortress is the first mTOR inhibitor approved to prevent organ rejection in adult liver transplant patients in the US, where it is already approved for kidney transplantation Approval based on
Medicine/Pharmacology
23.01.2013
Novartis drug Exjade first treatment approved by FDA for chronic iron overload in patients with non-transfusion-dependent thalassemia
Pivotal placebo-controlled study data show Exjade significantly decreases iron burden in NTDT patients versus placebo, with similar overall adverse event rate Patients with NTDT accumulate excess iron increasing their risk of complications, including liver fibrosis, cirrhosis, blood clots, and bone and vascular disease At least three quarters of a million people worldwide have NTDT - and many patients are undiagnosed until seri
Pivotal placebo-controlled study data show Exjade significantly decreases iron burden in NTDT patients versus placebo, with similar overall adverse event rate Patients with NTDT accumulate excess iron increasing their risk of complications, including liver fibrosis, cirrhosis, blood clots, and bone and vascular disease At least three quarters of a million people worldwide have NTDT - and many patients are undiagnosed until seri
Medicine/Pharmacology - Administration/Government
22.01.2013
Novartis receives EU approval for Bexsero , first vaccine to prevent the leading cause of life-threatening meningitis across Europe
Bexsero is indicated to help protect all age groups against meningococcal serogroup B (MenB) disease, including infants who are the most vulnerable MenB disease is associated with a high human
Bexsero is indicated to help protect all age groups against meningococcal serogroup B (MenB) disease, including infants who are the most vulnerable MenB disease is associated with a high human
Medicine/Pharmacology
18.01.2013
Novartis receives positive CHMP opinion for Ilaris to treat patients whose acute gouty arthritis cannot be managed with standard of care
CHMP endorsed the use of Ilaris in patients with acute gouty arthritis, who suffer frequent attacks and for whom current treatments are unsuitable or ineffective Ilaris, the only approved ful
CHMP endorsed the use of Ilaris in patients with acute gouty arthritis, who suffer frequent attacks and for whom current treatments are unsuitable or ineffective Ilaris, the only approved ful
Medicine/Pharmacology
18.01.2013
Jetrea(TM) receives positive CHMP opinion, would become the first drug to treat sight-threatening vitreomacular traction and macular hole
Pivotal data showed Jetrea significantly resolved vitreomacular traction (VMT) and macular hole compared to placebo at day 28 (p<0.001) Current standard of care for VMT is surgery or "watchf
Pivotal data showed Jetrea significantly resolved vitreomacular traction (VMT) and macular hole compared to placebo at day 28 (p<0.001) Current standard of care for VMT is surgery or "watchf
Medicine/Pharmacology - Business/Economics
17.01.2013
Novartis makes progress in the fight to eliminate leprosy worldwide
Novartis advances goals set as part of a coordinated, international effort to eliminate or control 10 neglected tropical diseases (NTDs) Over 500 facilities in Tanzania now use SMS for Life
Novartis advances goals set as part of a coordinated, international effort to eliminate or control 10 neglected tropical diseases (NTDs) Over 500 facilities in Tanzania now use SMS for Life
Medicine/Pharmacology - Administration/Government
14.01.2013
Pivotal study in The Lancet shows potential of Novartis vaccine Bexsero to help provide broad protection to infants against MenB
Phase III results show that Bexsero induced a robust immune response when administered concomitantly with routine vaccines, and also as a booster dose Data confirm Bexsero's acceptable safety and tolerability profile in infants, who are among the most vulnerable to MenB, a leading cause of meningitis Bexsero was recommended for European licensure in November 2012; upon approval, Bexsero will be the first and only broad cover
Phase III results show that Bexsero induced a robust immune response when administered concomitantly with routine vaccines, and also as a booster dose Data confirm Bexsero's acceptable safety and tolerability profile in infants, who are among the most vulnerable to MenB, a leading cause of meningitis Bexsero was recommended for European licensure in November 2012; upon approval, Bexsero will be the first and only broad cover
Medicine/Pharmacology - Life Sciences
11.01.2013
Phase III data in The Lancet show significant benefit of Novartis drug Afinitor in patients with non-cancerous tumors associated with TSC
More than 40% of TSC patients on everolimus had their kidney tumor volume reduced by at least half with no tumor progression Separate data show 35% of TSC patients treated with everolimus had their SEGA brain tumor volume reduced by one half or more Tuberous sclerosis complex (TSC), a genetic disorder, may cause non-cancerous tumors to form in vital organs, including the kidney and brain Basel, January 10, 2013
More than 40% of TSC patients on everolimus had their kidney tumor volume reduced by at least half with no tumor progression Separate data show 35% of TSC patients treated with everolimus had their SEGA brain tumor volume reduced by one half or more Tuberous sclerosis complex (TSC), a genetic disorder, may cause non-cancerous tumors to form in vital organs, including the kidney and brain Basel, January 10, 2013
Medicine/Pharmacology
21.12.2012
Novartis drug Exjade approved by European Commission
Novartis drug Exjade approved by European Commission for iron overload in patients with non-transfusion-dependent thalassemia Exjade is the first oral treatment approved in the EU for chronic iron overload in patients with non-transfusion-dependent thalassemia (NTDT) syndromes Pivotal placebo-controlled study data show Exjade significantly decreases iron burden in NTDT patients versus placebo, with similar overall adverse event
Novartis drug Exjade approved by European Commission for iron overload in patients with non-transfusion-dependent thalassemia Exjade is the first oral treatment approved in the EU for chronic iron overload in patients with non-transfusion-dependent thalassemia (NTDT) syndromes Pivotal placebo-controlled study data show Exjade significantly decreases iron burden in NTDT patients versus placebo, with similar overall adverse event
Medicine/Pharmacology
15.12.2012
Novartis drug Signifor gains FDA approval as the first medication to treat Cushing’s disease, a serious endocrine disorder
As the only pituitary-directed therapy, Signifor represents a novel therapeutic approach by addressing the underlying mechanism of Cushing's disease In the Phase III trial, most patients exp
As the only pituitary-directed therapy, Signifor represents a novel therapeutic approach by addressing the underlying mechanism of Cushing's disease In the Phase III trial, most patients exp
Medicine/Pharmacology - Administration/Government
11.12.2012
Two-year data show new Novartis drug Jakavi significantly reduced myelofibrosis disease burden and suggest overall survival advantage
Jakavi demonstrated rapid reductions in spleen size and improved quality of life in Phase III studies, with results sustained over two years COMFORT-II follow-up results show Jakavi may improve overall survival vs.
Jakavi demonstrated rapid reductions in spleen size and improved quality of life in Phase III studies, with results sustained over two years COMFORT-II follow-up results show Jakavi may improve overall survival vs.
Medicine/Pharmacology - Chemistry
10.12.2012
Novartis long-term Phase III data show Ph+ CML patients on Tasigna achieved significantly deeper molecular response versus Glivec
Both newly diagnosed patients and those switching to Tasigna after long-term treatment with Glivec achieved deeper molecular response with Tasigna Data suggest correlation between early mole
Both newly diagnosed patients and those switching to Tasigna after long-term treatment with Glivec achieved deeper molecular response with Tasigna Data suggest correlation between early mole
Medicine/Pharmacology - Psychology
04.12.2012
Novartis Foundation symposium discusses psychosocial support to help vulnerable children achieve mental health and wellbeing for a better future in sub-Saharan Africa
Symposium speakers assess psychosocial approaches and discuss various interventions to ensure mental health and wellbeing for Africa's children Experts present findings from
Symposium speakers assess psychosocial approaches and discuss various interventions to ensure mental health and wellbeing for Africa's children Experts present findings from
Medicine/Pharmacology - Chemistry
28.11.2012
Novartis highlights key data in patients with hematologic diseases and breast cancer with more than 140 abstracts at ASH and SABCS
Long-term follow-up data from Jakavi Phase III trials in patients with the debilitating blood cancer, myelofibrosis Updated Phase III data in patients with Ph+ CML who switched to Tasigna
Long-term follow-up data from Jakavi Phase III trials in patients with the debilitating blood cancer, myelofibrosis Updated Phase III data in patients with Ph+ CML who switched to Tasigna
|
||